We trace how sex and gender shape drug development, from male-heavy mouse studies to the split results in Lecanemab’s Alzheimer’s trial. Experts explain why regulators should keep approvals moving while demanding smarter design, better reporting, and post-approval answers.
For more science stories, visit our website swisinfo.ch, and you can help other people to find our podcast by leaving us a five-star review.
Journalist: Jessica Davis Plüss
Host: Jo Fahy
Audio editor/video journalist: Michele Andina
Distribution and Marketing: Xin Zhang
SWI swissinfo.ch is a public service media company based in Bern, Switzerland.
